Emergent Biosolutions
EBS
EBS
233 hedge funds and large institutions have $2.22B invested in Emergent Biosolutions in 2019 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 93 increasing their positions, 86 reducing their positions, and 61 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less capital invested
Capital invested by funds: $ → $
14% less funds holding
Funds holding: 272 → 233 (-39)
56% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 61
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Holders
233
Holding in Top 10
1
Calls
$53K
Puts
$43K
Top Buyers
| 1 | +$73.2M | |
| 2 | +$34.8M | |
| 3 | +$18M | |
| 4 |
Goldman Sachs
New York
|
+$16.3M |
| 5 |
State Street
Boston,
Massachusetts
|
+$16M |
Top Sellers
| 1 | -$30.3M | |
| 2 | -$17.7M | |
| 3 | -$12.9M | |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$11M |
| 5 |
MCM
Matarin Capital Management
New York
|
-$11M |